Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Caris Life SciencesCAI +5.14%11 Debt-to-EBITDA is 6.25 as of Mar. 2026. GuruFocus rates CAI with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 296 Biotechnology companies, Caris Life Sciences ranks worse than 73.31% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Caris Life Sciences's Debt-to-EBITDA or its related term are showing as below:
CAI'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.32 Med: -0.97 Max: 37.58
Current: 3.87
During the past 4 years, the highest Debt-to-EBITDA Ratio of Caris Life Sciences was 37.58. The lowest was -2.32. And the median was -0.97.
CAI's Debt-to-EBITDA is ranked worse than 73.31% of 296
companies
in the Biotechnology industry
Industry Median: 1.185
vs CAI: 3.87
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Caris Life Sciences Debt-to-EBITDA Related Terms
Caris Life Sciences Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Caris Life Sciences's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI vs EWTX, TNGX, LEGN: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Caris Life Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caris Life Sciences Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caris Life Sciences's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Caris Life Sciences's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Caris Life Sciences (CAI) has a Debt-to-EBITDA of 6.25 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Caris Life Sciences. According to the industry distribution chart, Caris Life Sciences ranks #217 out of 296 companies in the Biotechnology industry, placing it in the top 73.3%.
Is Caris Life Sciences' Debt-to-EBITDA too high?
Caris Life Sciences' current Debt-to-EBITDA is 6.25. The Biotechnology industry median Debt-to-EBITDA is 1.19. Caris Life Sciences' value of 6.25 is 427.4% above this industry median. Based on the distribution chart, Caris Life Sciences ranks #217 out of 296 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Caris Life Sciences has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Caris Life Sciences' Debt-to-EBITDA compare to EWTX and TNGX?
According to the Biotechnology industry distribution chart, Caris Life Sciences ranks #217 out of 296 companies for Debt-to-EBITDA. This places Caris Life Sciences in the lower half of its industry. The industry median Debt-to-EBITDA is 1.19. Caris Life Sciences' value of 6.25 is 427.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.19, based on 296 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caris Life Sciences's current Debt-to-EBITDA of 6.25 is 427.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Caris Life Sciences. For the Biotechnology industry, the median Debt-to-EBITDA is 1.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caris Life Sciences's current Debt-to-EBITDA is 6.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caris Life Sciences stock overvalued right now?
Caris Life Sciences (CAI) has a current Debt-to-EBITDA of 6.25. The current Debt-to-EBITDA is 6.25 and 427.4% above the Biotechnology industry median of 1.19. Caris Life Sciences' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Caris Life Sciences (CAI), the current Debt-to-EBITDA is 6.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
11GF Score
Get the complete analysis for CAI
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI has been successfully added to your 
